false
0001764046
0001764046
2026-09-23
2026-09-23
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities
Exchange Act of 1934
Date of Report (date of earliest event reported):
September 23, 2026
CLARIVATE PLC
(Exact name of registrant as specified in its charter)
| Jersey, Channel Islands |
| (State or other jurisdiction of incorporation or organization) |
| 001-38911 |
| (Commission File Number) |
| N/A |
| (I.R.S. Employer Identification No.) |
|
70
St. Mary Axe |
|
London
EC3A 8BE
|
|
United
Kingdom |
(44) 207-433-4000
Registrant's telephone number, including area code
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b)
of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
| Ordinary Shares, no par value |
CLVT |
New York Stock Exchange |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
On September 23, 2026, Clarivate Plc issued a press release announcing
the pricing terms of the previously announced cash tender offer by its wholly-owned subsidiary, Clarivate Science Holdings Corporation,
for certain of its debt securities. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| No. |
Description |
| 99.1 |
Press release issued by Clarivate Plc dated September 23, 2026 |
| 104 |
Cover page of this Current Report on Form 8-K formatted in Inline XBRL |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| |
CLARIVATE PLC |
| |
|
| Date: September 23, 2026 |
By: /s/ John Doulamis |
| |
Name: John Doulamis |
| |
Title: Senior Vice
President, General Counsel |
Exhibit 99.1
Clarivate
Announces Pricing Terms of Offer to Purchase for Cash Certain of its Outstanding Debt Securities
LONDON,
September 23, 2026: Clarivate Plc (NYSE: CLVT) ("Clarivate"), a leading global
provider of transformative intelligence, today announced the Reference Yield and Total Consideration (as set forth in the table below)
to be paid in connection with its previously announced cash tender offer (the "Offer") by its wholly-owned subsidiary, Clarivate
Science Holdings Corporation (the “Company”), to purchase the outstanding notes described below, upon the terms and subject
to the conditions set forth in the Offer to Purchase dated September 17, 2026 (the "Offer to Purchase").
The
Company is offering to purchase in the Offer its 3.875% Senior Secured Notes due 2028 (the "Notes") for the consideration described
below, subject to a $75,000,000 cap on the aggregate principal amount of Notes purchased in the Offer (the "Tender Cap") subject
to proration and the terms and conditions set forth in the Offer to Purchase. Subject to applicable law, the Company may, but is under
no obligation to, eliminate, increase or decrease the Tender Cap at any time prior to the "Expiration Date" of 5:00 p.m., New
York City time, on September 23, 2026 (unless extended or earlier terminated by the Company). In the event proration is required with
respect to the Notes, the Company will multiply the principal amount of each valid tender of such Notes by the proration rate and round
the resulting amount down to the nearest $1,000 principal amount in order to determine the principal amount of such tender that will
be accepted pursuant to the Offer. The excess principal amount of Notes not accepted from the tendering Holders will be promptly returned
to such Holders, and if this excess principal amount of Notes is less than $2,000, the Company may either accept or reject all such tendering
Holders' validly tendered Notes in its sole discretion. Additionally, the Company may increase the amount of Notes accepted for payment
in the Offer by no more than 2% of the outstanding Notes without amending or extending the Offer. The Offer to Purchase and any related
documents are referred to herein collectively as the "Tender Offer Documents". Capitalized terms used but not defined in this
press release have the meanings given to them in the Offer to Purchase.
Certain
information regarding the Notes and the pricing for the Offer is set forth in the table below.
| Notes |
Issuer
|
CUSIP
/ ISIN Number(1) |
Aggregate
Principal Amount Outstanding |
Reference
Security
|
Reference
Yield(2)
|
Bloomberg
Reference Page |
Fixed Spread
(Basis Points) |
Total
Consideration(3) |
| 3.875% Senior Secured Notes due 2028 |
Clarivate Science Holdings Corporation |
144A:
18064P AC3 / US18064PAC32
Reg
S: U1800Q AC3 / USU1800QAC34
|
$825,000,000 |
4.125% UST due June 30, 2028 |
4.864% |
FIT 4 |
+50 |
$975.15 |
| (1) | No
representation is made as to the correctness or accuracy of the CUSIP or ISIN numbers listed
above. |
| (2) | The
Reference Yield was determined at 2:00 p.m., New York time, on September 23, 2026. |
| (3) | Represents
the total consideration for the Notes (the "Total Consideration") payable per each
$1,000 principal amount of the Notes validly tendered and accepted for purchase in the Offer. |
The
"Total Consideration" payable per each $1,000 principal amount of Notes validly tendered for purchase is based on the Fixed
Spread, plus the Reference Yield based on the bid-side price of the Reference Security as quoted on the Bloomberg Reference Page as of
2:00 p.m., New York City time, today, September 23, 2026 (the "Price Determination Date"). In addition to the Total Consideration,
Holders whose Notes are accepted for purchase pursuant to the Offer will receive accrued and unpaid interest on those Notes from the
last interest payment date with respect to those Notes to, but excluding, the Settlement Date (the "Accrued Interest," and
the payment thereof, the "Accrued Coupon Payment").
Tenders
of Notes may be validly withdrawn at any time at or prior to 5:00 p.m., New York City time, today, September 23, 2026 (the "Withdrawal
Deadline"), but, except as provided in the Offer to Purchase or required by applicable law, may not be validly withdrawn thereafter.
The "Settlement Date" will be the second business day after the Expiration Date and is expected to be September 25, 2026.
The
complete terms and conditions of the Offer are set forth in the Tender Offer Documents. Holders are urged to read the Tender Offer Documents
carefully. If any condition to the Offer is not satisfied or waived, the Company is not obligated to accept for payment, purchase or
pay for, and may delay the acceptance for payment of, any tendered Notes, in each case subject to applicable law, and may terminate or
alter the Offer.
The
Company has retained Citigroup Global Markets Inc. to act as dealer manager (the "Dealer Manager") for the Offer. Global Bondholder
Services Corporation will act as the Tender and Information Agent for the Offer. For additional information, please contact: Citigroup
Global Markets Inc. at +1 (800) 558-3745 (toll-free) or +1 (212) 723-6106 (collect). Requests for documents and questions regarding the
tendering of Notes may be directed to Global Bondholder Services Corporation by telephone at (212) 430-3774 (for banks and brokers only)
and (855) 654-2015 (for all others toll-free) or to the Dealer Manager at its telephone number. Copies of the Offer to Purchase are available
at: https://www.gbsc-usa.com/clarivate/. You may also contact your broker, dealer, commercial bank, trust company or other nominee
for assistance concerning the Offer.
Holders
of Notes are advised to check with each bank, securities broker or other intermediary through which they hold Notes as to when such intermediary
would need to receive instructions from a beneficial owner in order for that Holder to be able to participate in, or withdraw their instruction
to participate in the Offer before the deadlines specified herein and in the Offer to Purchase. The deadlines set by any such intermediary
and DTC for the submission and withdrawal of tender instructions may be earlier than the relevant deadlines specified herein and in the
Offer to Purchase.
This
press release is neither an offer to purchase nor a solicitation of an offer to sell the Notes or any other securities. The Offer is
made only by and pursuant to the terms of the Offer to Purchase and only to such persons and in such jurisdictions as is permitted under
applicable law. The information in this press release is qualified by reference to the Offer to Purchase. None of the Company, Clarivate,
the Dealer Manager or the Tender and Information Agent makes any recommendation as to whether Holders should tender their Notes pursuant
to the Offer. Holders must make their own decisions as to whether to tender Notes, and, if so, the principal amount of Notes to tender.
Forward-Looking
Statements
This
release includes statements that express our opinions, expectations, beliefs, plans, objectives, assumptions, or projections regarding
future events or future results and therefore are, or may be deemed to be, “forward-looking statements” within the meaning
of the “safe harbor provisions” of the Private Securities Litigation Reform Act of 1995. These forward-looking statements
include all matters that are not historical facts, including statements relating to our intentions, beliefs, or current expectations
concerning, among other things, the completion of the Offer. These forward-looking statements can generally be identified by the use
of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,”
“seeks,” “projects,” “intends,” “plans,” “may,” “will,” or “should”
or, in each case, their negative or other variations or comparable terminology. Such forward-looking statements are based on available
current market material and management’s expectations, beliefs, and forecasts concerning future events impacting us. These forward-looking
statements involve a number of risks and uncertainties (some of which are beyond our control) or other assumptions that may cause actual
results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and
uncertainties include, but are not limited to, those factors described in Item 1A. Risk Factors in our annual report on Form 10-K, along
with our other filings with the U.S. Securities and Exchange Commission (“SEC”). There can be no assurance that future developments
affecting us will be those that we have anticipated. Should one or more of these risks or uncertainties materialize, or should any of
the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements.
We do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future
events or otherwise, except as may be required under applicable securities laws. Please consult our public filings with the SEC, which
are also available on our website at www.clarivate.com.
About
Clarivate
Clarivate
is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and
expert services in the areas of Academia & Government, Intellectual Property, and Life Sciences & Healthcare. For more information,
please visit www.clarivate.com.
Media
Contact:
Amy
Bourke-Waite, Senior Director, Communications & Brand
newsroom@clarivate.com
Investor
Relations Contact:
Mark
Donohue, Vice President, Investor Relations
investor.relations@clarivate.com